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Summary We previously demonstrated that colony stimulating factor (CSF)- producing cell lines co-produce
interleukin-l (IL-1) and IL-6 in addition to CSFs. In the present study, we examined the role of IL-1
production in three human tumour cell lines producing granulocyte (G)-CSF, IL-l and IL-6. Addition of
anti-human IL-la antiserum to the culture caused a 90-62% reduction of G-CSF and a 85-44% reduction of
IL-6 production, respectively, as evaluated by enzyme immunoassay in all three cell lines. The decrease of
G-CSF and IL-6 production by the anti-IL-la antiserum was also confirmed at the level of mRNA expression.
The anti-IL-la antiserum did not affect the growth of these cell lines. Excess recombinant IL-la exogenously
added to the culture enhanced G-CSF and IL-6 production in all three cell lines. However, IL-la had little
effect on the growth of these three cell lines. Neither anti-IL-6 nor anti-G-CSF antibodies affected the
production of the other cytokines. These results indicate that IL-la regulates G-CSF and IL-6 production in
these tumour cell lines, and suggest that the IL-1 production plays an important role in CSF-producing
tumours.
Colony stimulating factor (CSF) is produced by certain
malignant tumours. In recent years, some CSF-producing
tumours have been shown to elaborate not only CSF but
also either interleukin-1 (IL-1) or IL-6, or both (Demetri et
al., 1989; Sato et al., 1989). Recently, we reported an addi-
tional multicytokine-producing lung carcinoma cell line
(KHC287) (Suzuki et al., 1991). Regarding multicytokine
production, we examined a larger number of CSF-producing
cell lines and found that IL-1 and IL-6 were produced in
addition to CSFs in all the lines examined (Okuno et al.,
1991).
These facts raised a question of which cytokine regulates
the production of other two. IL-I stimulates CSF and IL-6
production in normal fibroblasts (Seelentag et al., 1989),
macrophages (Fibbe et al., 1986), endothelial cells (Fibbe et
al., 1989) and bone marrow stromal cells (Slack et al., 1990).
We therefore examined the role of IL-I production in three
human tumour cell lines co-producing IL-1 and IL-6 in
addition to granulocyte (G)-CSF.
Materials and methods
CSF-producing cell lines
KHC287 (Suzuki et al., 1991) was established in our
laboratory in 1987, from a patient with large cell type lung
carcinoma. CHU-2 (Nagata et al., 1986) (oral cavity
squamous carcinoma) was kindly provided by Dr S. Asano,
University of Tokyo. A bladder carcinoma cell line, T24
(Hirano et al., 1986) was provided by the Japanese Cancer
Research Resources Bank. The production of G-CSF, IL-1
and IL-6 by these three cell lines has been previously de-
scribed (Okuno et al., 1991; Suzuki et al., 1991). The non-
CSF-producing cell line, HeLa, was examined as the control.
Growthfactors and antibodies
Recombinant (r) human IL-la and IL-6 were purchased from
Genzyme Co. Ltd (Boston, MA, USA), and human rG-CSF
was provided by Chugai Pharmaceutical Co. Ltd (Tokyo,
Japan). The endotoxin levels in these recombinant cytokines
were below GMP (good manufacture practice) permissible
levels.
Anti-human IL-la rabbit antiserum (OCT323K) was pro-
vided by Ohtsuka Pharmaceutical Co. Ltd (Tokushima
Research Institute, Japan). Sixty ,Lg of OCT323K protein can
completely neutralise 12 ng of human IL-la. Anti-human
G-CSF mouse monoclonal antibody (MoAb) (IgGj), was
provided by Chugai Pharmaceutical Co. Ltd, and 5 .g of
which can completely neutralise 100 ng of human G-CSF.
Anti-human IL-6 mouse MoAb (MH166, IgG,) (Matsuda et
al., 1988), was also provided by Chugai Pharmaceutical Co.
Ltd, 10 jig of which can completely neutralise 10 ng of
human IL-6. Normal rabbit serum and mouse myeloma
monoclonal protein MOPC21 (IgGj, Cappel, Cochranville,
PA) were used as control antibodies.
Cell culture
Cells (1 x IO' ml-1) from each line were washed twice and
cultured in RPMI-1640 medium (Nissui, Tokyo, Japan) sup-
plemented with 10% fetal calf serum (FCS, Hyclone, Logan,
UT, USA) for 3 days with or without antiserum, MoAb or
recombinant cytokine. Culture supernatants were collected
for G-CSF, IL-1 and IL-6 assay. Cultures were performed in
triplicate.
Evaluation ofcell growth
Cells were cultured with or without antiserum, MoAb or
recombinant cytokine for 2 days followed by a 12 h pulse of
tritiated thymidine (5pCi ml-1) ([3H]-TdR, NEN, Boston,
MA), the incorporation of which was measured by a liquid
scintillation counter. Cell growth was also evaluated by coun-
ting cell numbers. As cells used in this study proliferate as
plastic adherent cells, cells were detouched with trypsin-
EDTA solution (Gibco, Grand Island, NY), then cell count-
ing was performed using a haemocytometer.
Enzyme-linked immunosorbent assay (ELISA)
G-CSF concentrations of the culture supernatants were
measured by ELISA as previously described (Watari et al.,
1989). IL-la, and IL-6 concentrations were measured by
ELISA kits purchased from Ohtsuka Pharmaceutical Co. Ltd
(Tokyo, Japan) and Genzyme Co. Ltd (for IL-6), respec-
tively.
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Northern blotting
The following experiments were carried out under the regula-
tions of the Committee for Recombinant DNA Experiments,
Kyoto University.
Total cellular RNA (20gig) was extracted from cells by the
acid-phenol method (Chromczynski & Sacchi, 1987) and
Northern blot hybridisation was performed according to the
standard method described elsewhere (Maniatis et al., 1982).
The cDNA probes for IL-la, IL-6 and G-CSF were kindly
provided by Dainippon Pharmaceutical Co. Ltd, Dr T.
Hirano (Osaka University, Japan) and Chugai Pharma-
ceutical Co. Ltd, respectively. A ,-actin probe was used to
evaluate the loading amount of RNA. Signals on the
autoradiograms were quantitated by densitometry.
tively, when the signals were quantitated by densitometry.
Similarly, the reduction in IL-6 mRNA levels was estimated
at 70%, 70% and 60% in T24, KHC287 and CHU-2, respec-
tively.
Anti-IL-la antiserum did not affect the measurement of
G-CSF and IL-6 concentrations by ELISA when added to
the assay medium containing G-CSF or IL-6 even at a dose
of 50jig ml-'. Also anti-IL-la antiserum did not inhibit
G-CSF-induced in vitro granulocyte colony formation
(Suzuki et al., 1991), and did not affect the IL-6 bioassay
with an IL-6-dependent murine hybridoma cell line,
MH60BSF2 (Kawano et al., 1988) (data not shown).
Statistical analysis
The statistical significance of the values was analysed using
the student's t-test.
Results
Effect ofanti-IL-lc antiserum on G-CSF and IL-6production
Tables I and II show the representative results from repeated
experiments. Anti-IL-la antiserum inhibited G-CSF produc-
tion dose-dependently in T24, KHC287 and CHU-2 cell lines
as evaluated by ELISA (Table I). The reduction in G-CSF
production ranged from 90-62% at the maximum dose
(50 gg protein ml-') of the anti-IL-ka antiserum added.
Table II shows the effect of the anti-IL-la antiserum on IL-6
production in the three cell lines. Similar to G-CSF, IL-6
production was inhibited dose-dependently in all three cell
lines, although the degree of inhibition was slightly lower
than that in G-CSF production; the reduction ranged from
85 to 44% at the maximum dose (50jig ml-') of the
antiserum added.
The inhibition of G-CSF and IL-6 production by the anti-
IL-ka antiserum was confirmed at the level ofmRNA expres-
sion. As shown in Figure 1, the levels of G-CSF and IL-6
mRNA expression were clearly decreased by anti-IL-lDx
antiserum (50gig ml-'). The reduction of the G-CSF mRNA
level caused by the anti-IL-la antiserum was estimated to be
60%, 80% and 70% in T24, KHC287 and CHU-2, respec-








Figure 1 Inhibitory effect of anti-IL-la antiserum on G-CSF
and IL-6 mRNA expression as analysed by Northern blotting in
three G-CSF-producing cell lines. Total cellular RNA (20gig) was
electrophoresed and serially hybridised with G-CSF (a), IL-6 (b)
and P-actin (c) probes. Lanes 1 and 2, RNA from T24 cells;
Lanes 3 and 4, RNA from KHC287 cells; Lanes 5 and 6, RNA
from CHU-2 cells. Lanes 1, 3 and 5, RNA from cells cultured
with normal rabbit serum (50gig ml-') for 24 h; Lanes 2, 4 and 6,
RNA from cells cultured with anti-human IL-la rabbit antiserum
(OCT323K, 50gigml-') for 24h; Lane 7, RNA from Hela cells
cultured without antiserum.
Table I Effect of anti-human IL-lk rabbit antiserum on G-CSF production in 3 G-CSF-producing cell lines
G-CSF concentrations (pgml-')
T24 (% of control) KHC287 (% ofcontrol) CHU-2 (% of control)
No antiserum 21 376 ± 1853 (100) 172 732 ± 3035 (100) 66 915 ± 1965 (100)
Anti IL-laantiserum (5ngml-') 18 347± 892 ( 86) 166308 13165 ( 96) 60899± 117 ( 91)
Anti IL-laantiserum(5Ongml-') 14987±1116 ( 70) 154349± 9199 ( 89) 54 193±2561* ( 81)
Anti IL-lo antiserum (500 ngml-') 11 077 1143* ( 52) 129 854 3926** ( 75) 43 945 ± 3657* ( 66)
Anti IL-la antiserum (5 gig ml-) 4 266 ± 205** ( 20) 83 682 ± 2398** ( 48) 32 389 ± 260** ( 48)
Anti IL-Ixantiserum (50jigml-') 2058± 13**( 10) 39063± 3254**( 23) 25 526± 542**( 38)
Normal rabbit serum (50gigml-') 24 147± 546 (113) 158 860± 5304 ( 92) 66 303± 3133 ( 99)
Cells(1 x IO' ml- )werecultured for3 dayswith orwithoutanti-human IL-larabbit antiserum. G-CSFconcentrationsinthe
culture supernatants were measured by ELISA. The lower limit ofdetection in the ELISA kit for G-CSF was 60 pg ml-'. Each
value represents m ± s.e. (n = 3). Number in the parenthesis indicates the protein concentrations ofthe antiserum added to the
culture. *:P < 0.05 and **:P < 0.01 as compared to the value of control culture (no antiserum).
Table II Effect of anti-human IL-la rabbit antiserum on IL-6 production in 3 G-CSF-producing cell lines
T24 (% ofcontrol)
IL-6 concentrations (pgml')
KHC287 (% ofcontrol) CHU-2 (% ofcontrol)
No antiserum 15 867 ± 2239 (100) 181 666 ± 3605 (100) 17 300 ± 983 (100)
Anti IL-k antiserum ( 50 gml-') 2 307 ± 200** ( 15) 102 250 ± 1930** ( 56) 9 342± 538** ( 54)
Normal rabbitserum( 50ggml-') 18 267± 757 (115) 190 876±4846 (105) 19 866±569 (115)
Cells (1 x 105ml-') were cultured for 3 days with or without anti-human IL-ka rabbit antiserum. IL-6 concentrations in the
culture supernatants were measured by ELISA. The lower limit ofdetection in the ELISA kit for IL-6 was 100 pg ml-. Each
value represents m ± s.e. (n = 3). Number in the parenthesis indicates the protein concentrations ofthe antiserum added to the
culture. **:P<0.01 as compared to the value of control culture (no antiserum).G-CSF PRODUCING TUMOUR AND IL-1 517
Effect ofanti-G-CSF and anti-IL-6 antibodies on cytokine
production
Anti-human G-CSF MoAb (10 tg ml-') did not affect the
production of IL-lk and IL-6 in all three tumour cell lines as
evaluated by ELISA. Similarly, anti-human IL-6 MoAb
(MH166) (10gg) did not affect the production of G-CSF and
IL-lk (data not shown).
Effect of exogenous IL-lot on G-CSF and IL-6 production
The levels of IL-ka production by T24, KHC287 and CHU-2
were 230, 163 and 266 pg ml- 1, respectively, as evaluated by
ELISA at day 3 of culture. IL-1lB levels at the same culture
period were 18, 53 and 62 pg ml 1, respectively. The
measurements on IL-ka and IL-1p were performed three
times, and these results were reproducible in repeated
experiments. The concentrations of IL-la produced by these
three cell lines corresponded to approximately 20 U ml-' of
the rIL-la used in this study, therefore, we examined the
effect of excess rIL-la on G-CSF and IL-6 production by
these three cell lines.
As shown in Table III, 100 U ml-' (1 ng ml-') of rIL-la
but not 10 U ml-', enhanced G-CSF and IL-6 production in
all three cell lines as evaluated by ELISA. Similar results
were obtained from repeated experiments.
Neither exogenous rG-CSF nor rIL-6 promoted further
production on IL-lk and IL-6, or G-CSF and IL-ka, respec-
tively, even at a dose of 1 jig ml-' in all three cell lines (data
not shown).
Effect ofantibodies or cytokines on cell growth
Anti-IL-lk antiserum, anti-G-CSF MoAb, anti-IL-6 MoAb
(MH166), rIL-la, rG-CSF and rIL-6 had little effect on the
cell growth in each cell line as examined by [3H]-TdR incor-
poration or counting cell numbers (data not shown).
Discussion
In the present study, we demonstrated that G-CSF and IL-6
production was clearly suppressed by anti-IL-lk antiserum in
three tumour cell lines producing G-CSF, IL-1 and IL-6.
Il-km production was not affected by anti-G-CSF or anti-IL-6
antibodies. Also anti-G-CSF and anti-IL-6 antibodies did not
inhibit IL-6 and G-CSF production, respectively. Further-
more, excess exogenous IL-ka caused further production of
G-CSF and IL-6 in all three cell lines. On the other hand,
addition of exogenous G-CSF and IL-6 did not stimulate the
production of the other cytokines in all three cell lines. These
results indicate that IL-ka regulates the production of G-CSF
and IL-6 in these three cell lines, and suggest that the IL-lk
production plays an important role in G-CSF or IL-6 pro-
duction in CSF-producing tumours. To our knowledge, there
has been no report describing the IL-1 production as the
regulator of CSF and IL-6 production in CSF-producing
tumours. The relationship among these three cytokines
appears to be similar to that in normal stromal cells or
fibroblasts (Schaafsma et al., 1989). It remains to be deter-
mined, however, whether expression of IL-la gene initiated
the G-CSF and IL-6 gene activation or only enhanced
already activated genes.
In the present study, anti-IL-ka antiserum did not bring
complete inhibition of G-CSF or IL-6 production. Presum-
ably, this is due to IL-1lB being co-produced in all three cell
lines (Okuno et al., 1991; Suzuki et al., 1991) or a suboptimal
dose of anti-IL-lk antiserum being insufficient for the com-
plete abolishment of IL-lk continuously produced in situ by
these cells. Tumour necrosis factor-oc (TNF-a) could be
another candidate for the incomplete inhibition of G-CSF
and IL-6 production. However, TNF-a was detectable
(95.1 pg ml ') only in the culture supernatant of CHU-2
(Okuno et al., 1991). Nevertheless, residual activities of G-
CSF and IL-6 were noted in all three cell lines. It may be
unlikely, therefore, that TNF-a regulates G-CSF and IL-6
production besides IL-lk in these three cell lines.
Neither anti-IL-lk antiserum nor exogenous IL-lk affected
the growth of these three cell lines. These results suggest that
the autocrine growth mechanism through IL-kla is not
operating in these lines. Furthermore, it appears unlikely that
the inhibition of G-CSF and IL-6 production by the anti-IL-
la antiserum was caused secondarily by the growth inactiva-
tion of these three cell lines, because the anti-IL-lk antiserum
did not affect the cell proliferation of these lines. Alterna-
tively, in the present study, we could examine the role of
IL-lk in the production of G-CSF and IL-6 in the functional
aspect (cytokine production) of tumour cell lines which pro-
liferate independently of these three cytokines.
We (Suzuki et al., 1991 and Nishizawa et al., 1990) showed
that in G-CSF producing tumour cell lines, some transac-
tivating factors which bind to the upstream region of the
G-CSF gene play an important role in abnormal G-CSF gene
expression. Furthermore, a transactivating factor (NF-IL-6)
which binds to the upstream region of the IL-6 gene is
operating as the main factor for IL-6 production in a glio-
blastoma cell line (SK-MG-4) stimulated by IL-l (Akira et
al., 1990). We are currently examining whether or not the
level of IL-1 gene expression correlates with the levels of
these transactivating factors which promote the transcription
of G-CSF and IL-6 genes to elucidate the exact relationship
between IL-l gene expression and G-CSF or IL-6 produc-
tion.
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Table III Effect of IL-la on G-CSF and IL-6 production in 3 G-CSF-producing cell lines
T24 KHC287 CHU-2
IL-lot added G-CSF (pgml-') IL-6 (pgml-') G-CSF (pg ml-') IL-6 (pg ml-') G-CSF (pg ml-') IL-6 (pgml-')
None 21 376 ± 1855 15 867 ± 2239 172 732 ± 3035 179 666 ± 2126 66 915± 1968 17 300 ± 983
10 U ml-, 27 251 ± 875 20 989 ± 1734 172 743 ± 1973 187 700 ± 3269 72 561 ± 1673 22 400 ± 1671
100 Uml-, 29 593± 2626* 49 939± 2392t 192 096± 2984* 193 733 ± 1953* 91 224± 1225t 26 834± 2387*
Cells (1 x 105 ml-') were cultured for 3 days with or without r-human-IL-la. Concentrations ofG-CSF and IL-6 in theculture supernatants
were measured by ELISA. Each value represents m ± s.e. (n = 3). *P<0.05 and tP<0.01 compared with the value ofcontrol culture (without
cytokine).518 A. SUZUKI et al.
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